Search
Deflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD).
Synonyms: 11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE, 5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor. … [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence
Bleselumab
go.drugbank.com/drugs/DB15253InvestigationalBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney
Tubercidin
go.drugbank.com/drugs/DB03172ExperimentalAn antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids
Synonyms: Sparsomycin AAlizapride
go.drugbank.com/drugs/DB01425InvestigationalAlizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.
Categories: Dopamine D2 Receptor AntagonistsProtein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]
XP12B
go.drugbank.com/drugs/DB04928InvestigationalIt was granted Fast Track status for this indication by the FDA in November 2004.
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on